Results 61 to 70 of about 50,237 (216)

Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expression

Scientific Reports
Colorectal cancer (CRC) often necessitates cetuximab (an EGFR-targeting monoclonal antibody) for treatment. Despite its clinical utility, the specific operative mechanism of cetuximab remains elusive.
Xiaohong Zhang, Wenming Zhou, Chenqu Wu, Jun Jiang, Qianqian Guo, Li Feng, Xun Cheng, Xingxing Zhang   +7 more
doaj   +1 more source

Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145

Radiation Oncology, 2021
Background Epidermal Growth Factor Receptor is often overexpressed in advanced prostate carcinoma. In-vitro-studies in prostate carcinoma cell line DU145 have demonstrated increased sensibility to radiation after cetuximab treatment, but clinical data ...
Raik Schneider, Günther Gademann, Hans-Joachim Ochel, Karsten Neumann, Burkhard Jandrig, Peter Hass, Mathias Walke, Martin Schostak, Thomas Brunner, Frank Christoph   +9 more
doaj   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation

, 2022
ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D ...
Paul Michael Waring (13470313), Harpreet Wasan (13744969), Lorraine A Chantrill (13470328), Louise A Nott (13744972), Nick Pavlakis (783392), Eva Segelov (13470334), Mustafa Khasraw (13078896), Michael Jefford (3609779), Val Gebski (732415), Andrew Mark Haydon (13744981), T J Price (13408860), Guy Van Hazel (13744978), Kate Wilson (4620691), Josep Tabernero (13744966), Jayesh Desai (810277), Jeremy David Shapiro (13470331), Craig Underhill (13470325), Warren Lance Joubert (13744975), Fortunato Ciardiello (336927), Christos Stelios Karapetis (13355727)   +19 more
core  

Craniofacial Resection for Advanced Cutaneous Squamous Cell Carcinoma: Results From the 2nd International Collaborative Case‐Series

Head &Neck, EarlyView.
ABSTRACT Background Robust outcome data for anterior skull base cutaneous squamous cell carcinoma (cSCC) are limited, particularly as emerging therapies reshape management. We evaluated survival and prognostic factors following craniofacial resection. Methods Retrospective multi‐institutional case‐series (1995–2015) of patients who underwent skull base
Michael J. C. Schachtel, Benedict J. Panizza, James J. Bowman, Catherine Barnett, Cristina Valero, Ian Ganly, Snehal G. Patel, Helena Levyn, Dauren Adilbay, Alana Eagan, Marc A. Cohen, Lillian A. Boe, Junting Zheng, Mithat Gonen, Prathamesh Pai, Paolo Castelnuovo, Fang Ju Gao, Cesare Piazza, Piero Nicolai, Luiz P. Kowalski, Ronaldo N. Toledo, Claudio Cernea, Sergio Goncalves, Dan M. Fliss, John R. de Almeida, Ian Witterick, Philippe Herman, Walter Fontanella, Gregorio Sanchez Aniceto, Alvaro Rivero Calle, Sefik Hosal, Serdar Ozer, Subramania Iyer, Richard J. Harvey, C. Rene Leemans, Jan‐Jaap Hendrickx, Marcelo Figari, Luis Boccalatte, Ken Ichi Nibu, Peter Clarke, Catherine Rennie, Yiming Zhu, Rodney J. Schlosser, Fernando L. Dias, Zoukaa Sargi, Shahzada Ahmed, Wojciech Golusinski, Se Heon Kim, Shirley Y. Su, Shaan M. Raza, Franco DeMonte, Ehab Hanna, Jatin P. Shah   +52 more
wiley   +1 more source

Best response of SCT (paclitaxel and cetuximab).

, 2022
Best response of SCT (paclitaxel and cetuximab).
Toranoshin Takeuchi (13170775), Takashi Nakagawa (125942), Takahiro Wakasaki (4371490), Rina Jiromaru (13170778), Moriyasu Yamauchi (13170769), Yuichiro Kuratomi (13170772), Tomomi Manako (13170766), Muneyuki Masuda (700171), Hirotaka Hara (635939), Satoshi Toh (369369), Emi Nishimura (2450674), Ryuji Yasumatsu (6802775), Mioko Matsuo (700163), Kazuki Hashimoto (1784377), Noritaka Komune (13170781)   +14 more
core   +1 more source

Head and Neck Lymph Node Metastases From Cancer of Unknown Primary: Outcomes From p16‐Guided Mucosal Radiotherapy

Head &Neck, EarlyView.
ABSTRACT Background The AJCC 8th edition distinguishes p16‐positive oropharyngeal head and neck carcinoma of unknown primary (HNCUP) due to its superior prognosis. However, standardized radiation volume guidelines are lacking. This study evaluates the safety of p16‐guided mucosal volume reduction.
Philippe Harris, Dhiya‐Eddine Mabrouki, Felix‐Phuc Nguyen‐Tan, Edith Filion, Olivier Ballivy, Brian O'Sullivan, Apostolos Christopoulos, Tareck Ayad, Louis Guertin, Eric Bissada, Paul Tabet, Denis Soulières, Antoine Desilets, Alexandre Pellan Cheng, Robert Doucet, Laurent Létourneau‐Guillon, Houda Bahig   +16 more
wiley   +1 more source

HOXB8 mediates resistance to cetuximab in colorectal cancer cells through activation of the STAT3 pathway

Discover Oncology
Homeobox B8 (HOXB8) belongs to the HOX family and was essential to the development of colorectal carcinoma. Among the prevalent monoclonal antibodies for treating RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients, cetuximab stands out, but ...
Yunan Liang, Han Lin, Zongsheng Jiang, Qi Zhao, Ri Cui, Shaotang Li   +5 more
doaj   +1 more source

Cetuximab induced aseptic meningitis [PDF]

, 2015
We report a 67-year-old man with recurrent advanced oropharyngeal squamous cell carcinoma who developed aseptic meningitis, with first symptoms arising approximately 9hours after the first administration of cetuximab, and review the literature to ...
Ulrich, A, Weiler, S, Weller, M, Rordorf, T, Tarnutzer, A A; https://orcid.org/, Weller M, Rordorf T, Ulrich A, Weiler S, Tarnutzer AA   +9 more
core   +1 more source

Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Spread: A Systematic Review

Head &Neck, EarlyView.
ABSTRACT Background Immunotherapy is increasingly used for head and neck cutaneous squamous cell carcinoma (cSCC) with perineural spread (PNS), though outcomes remain poorly defined. Methods A systematic review was conducted according to PRISMA and MOOSE guidelines.
Jai Paris, James Tsimiklis, Ayushi Agarwal, Jessica Y. Tong, Dinesh Selva   +4 more
wiley   +1 more source